copy and paste this google map to your website or blog!
Press copy button and paste into your blog or website.
(Please switch to 'HTML' mode when posting into your blog. Examples: WordPress Example, Blogger Example)
Input Form:Deal with this potential dealer,buyer,seller,supplier,manufacturer,exporter,importer
(Any information to deal,buy, sell, quote for products or service)
Estimating the Clinical and Economic Value of Aztreonam-Avibactam for . . . ATM-AVI was assessed as a first-line treatment, within the existing two-line treatment strategy (colistin + meropenem and colistin + aminoglycoside) Efficacy, resistance, adverse events, and cost inputs were sourced from the phase 3 REVISIT trial, literature and local expert opinion
Estimating the Value of Aztreonam-Avibactam in Treating Metallo-beta . . . This study aims to estimate the value of adding ATM-AVI as a new first-line treatment into the current strategy (ATM-AVI → cefiderocol → colistin + meropenem) in patients with hospital-acquired ventilator-associated pneumonia (HAP VAP) and complicated intra-abdominal infections (cIAI), caused by MBL-EB from the Spanish NHS perspective
Estimating the Value of Aztreonam-Avibactam in Treating Metallo-beta . . . This study aims to estimate the value of adding ATM-AVI as a new first-line treatment into the current strategy (ATM–AVI → cefiderocol → colistin + meropenem) in patients with hospital-acquired ventilator-associated pneumonia (HAP VAP) and complicated intra-abdominal infections (cIAI), caused by MBL-EB from the Spanish NHS perspective
Aztreonam–avibactam for the treatment of serious infections caused by . . . We report results of the ASSEMBLE study evaluating the efficacy and safety of aztreonam–avibactam versus best available therapy (BAT) in the treatment of serious infections caused by MBL-producing MDR pathogens for which there are limited or no treatment options
€1. 54 billion - ispor. org This study assessed the value and cost-efectiveness of ATM-AVI for the treatment of hospital-acquired infections caused by suspected MBL-PE in Greece, considering the transmission and diversity value of the STEDI framework
Estimating the Value of Aztreonam-Avibactam in Treating Metallo-beta . . . This study aims to estimate the value of adding ATM-AVI as a new first-line treatment into the current strategy (ATM–AVI → cefiderocol → colistin + meropenem) in patients with hospital-acquired ventilator-associated pneumonia (HAP VAP) and complicated intra-abdominal infections (cIAI), caused by MBL-EB from the Spanish NHS perspective
Cost-Effectiveness Analysis of Aztreonam-Avibactam (ATM-AVI) Versus . . . Our analysis suggests that ATM-AVI is expected to be a cost-effective use of Italian healthcare resources for treating suspected metallo-β-lactamase-producing Enterobacterales, including complicated intra-abdominal infection and hospital-acquired pneumonia ventilator-associated pneumonia
Estimating the Value of Aztreonam-Avibactam in Treating Metallo-beta . . . A dynamic disease transmission model was developed to assess the value of ATM-AVI considering the transmission, diversity and enablement components of the value framework for antibiotics, called STEDI (spectrum, transmission, enablement, diversity, insurance)